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Abstract
Background:
In order to weigh the risks of surgery against the presumed advantages, it is 
important to have specific knowledge about complication rates. 
Objective:
To study the surgical mortality and rate of reoperations for hematomas and infections 
after intracranial surgery for brain tumors in a large, contemporary, single-institution 
consecutive series. 
Material & Methods:
All adult patients from a well-defined population of 2.7 mill. inhabitants who 
underwent craniotomies for intracranial tumors at Oslo University Hospital during 
2003 to 2008 were included (n=2630). The patients were identified from our 
prospectively collected database and their charts studied retrospectively. Follow-up 
was 100%. 
Results:
The overall surgical mortality, defined as death within 30 days of surgery, was 2.3% 
(n=60). The mortality rates for high- and low-grade gliomas, meningiomas, and 
metastases were 2.9%, 1.0%, 0.9%, and 4.5%, respectively. Age>60 (Odds ratio 
1.84, p<0.05) and biopsy compared to resection (Odds ratio 4.67, p<0.01) were 
significantly positively associated with increased surgical mortality. Hematomas 
accounted for 35% of the surgical mortality. Postoperative hematomas needing 
evacuation occurred in 2.1% (n=54). Age >60 was significantly correlated to 
increased risk of postoperative hematomas (Odds ratio 2.43, p<0.001). A total of 39 
patients (1.5%) were reoperated for postoperative infection. Meningiomas had an 
increased risk of infections compared to high grade gliomas (Odds ratio 4.61, 
p<0.001). 
Conclusions: 
Mortality within 30 days of surgery was 2.3%, with age >60 and biopsy vs. resection 
being the two factors significantly associated with increased mortality. Postoperative 
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hematomas caused about one third of the surgical mortality. The overall risk 
associated with surgery for intracranial tumors is low.
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Introduction
According to The Central Brain Tumor Registry of the United States (CBTRUS), the 
incidence rate of all primary brain and central nervous system (CNS) tumors is 16.5 
cases per 100,000 person–years (9.2 per 100,000 person–years for non–malignant 
tumors and 7.3 per 100,000 person–years for malignant tumors) 1. The prevalence 
rate for all primary brain and central nervous system tumors was estimated to be 
130.8 per 100,000 inhabitants 1. Metastatic brain tumors are thought to have a higher 
incidence than primary brain tumors 2. 
The cornerstone of brain tumor treatment is surgery. The objective of surgery is to re-
move as much tumor as possible, as well as to establish an exact tissue diagnosis. 
The possible benefits of tumor removal include symptom relief, improved quality of 
life, smaller tumor burden for other treatment modalities and improved survival 3-9. 
However, craniotomies are not without inherent risks, be it surgical mortality 10, 11, 
postoperative hematomas 12, 13 or infection 14. With respect to surgical mortality, the 
reported series are often of limited size 15 and based on a selected patient group 16. 
Furthermore, to ascertain surgical deaths, either death before discharge (in-hospital 
mortality) or within 30 days of surgery is used, with the former missing more than 
25% of surgery-related deaths and creates potential for bias across institutions (John 
D. Birkmeyer, personal communication). With respect to intracranial hematomas, the 
consequences are often devastating, with a mortality rate of 30% and a significant 
morbidity rate 17. With respect to infections after neurosurgical procedures, these of-
ten present as meningitis, subdural empyema, or cerebral abscess. Although men-
ingitis can often be treated with intravenous antibiotics, cases that involve a bone flap 
infection, subdural empyema, or cerebral abscess usually require a repeated opera-
tion.
In order to weigh the risks of surgery against the presumed advantages, it is import-
ant to have specific knowledge about the institution’s complication rate. We therefore 
wanted to determine the 30 day surgical mortality rate as well as the rate of post-
craniotomy hematomas and infections that required reoperation, reviewing our pro-
spectively collected database of 2630 craniotomies for tumors performed between 
5
2003 and 2008. 
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Materials and methods
Patients
The defined neurosurgical catchment area for Oslo University Hospital is the south 
and eastern health region of Norway. It has 2.7 million inhabitants (56% of the 
Norwegian population) and Oslo University Hospital treat approximately 99% of the 
neurosurgical tumor patients within this region (The Norwegian Cancer Registry, 
unpublished data). All patients ≥18 years who underwent craniotomy for an 
intracranial tumor at the two departments of Oslo University Hospital (Rikshospitalet 
and Ullevål) in the time period 2003 – 2008 were included in this study. Thus, this 
study can also serve as a population study in terms of incidence of craniotomies for 
particular tumor types in Norway. Patients who underwent stereotactic biopsy were 
not included. 
The patients were identified from our prospectively collected database and their 
charts were studied retrospectively. The following data were recorded: sex, age, 
biopsy or resection, primary or secondary (repeated) surgery, histology, reoperation 
for postoperative hematoma, and reoperation for deep postoperative infection 
(infected bone flap, epidural abscess, subdural empyema or intracerebral abscess). 
Superficial wound infections that required simple wound revision were not included. 
Surgical mortality was defined as death within 30 days of surgery. Vital status (dead 
or alive) and time of death was obtained from the Norwegian Population Registry 
(Folkeregisteret) February 28th, 2009.
The charts of the patients who died within 30 days, or who were reoperated for 
hematoma or infection, were studied more thoroughly. The cause of death for those 
who died within 30 days was recorded as directly surgery-related (SR), i.e. 
hemorrhage or postoperative edema with subsequent herniation, or not surgery-
related (NSR), i.e. either tumor progression-related, systemic complications, or other 
causes. The time from initial surgery to reoperation for hematoma or infection was 
recorded. The long-term outcome for those reoperated for hematoma or infection 
was determined, based on preoperative status, postoperative recovery, both after the 
original craniotomy and reoperation, and status at follow-up contacts with the 
hospital. The patient’s condition at follow-up was compared with the patient’s 
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expected disability had he not suffered such complications, thus giving an estimate of 
additional disability likely caused by the hematoma or infection. The following scale 
was used: no additional disability, minor additional disability, major additional 
disability, and death.
The major histological groups were used (Table 1), with low-frequency tumor types 
grouped as others. The gliomas were divided into two groups: High-grade gliomas 
(HGG), and low-grade gliomas (LGG). The HGG-group included glioblastoma 
multiforme (WHO grade IV), primitive neuroectodermal tumor (PNET) (WHO grade 
IV), anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic 
oligodendroglioma, and anaplastic ependymoma (all WHO grade III). The LGG-group 
included all other astrocytic, oligodendroglial, ependymal tumors (WHO grade I and 
II), and also ganglioglioma (WHO grade I), DNET (WHO grade I), and choroid plexus 
tumors (WHO grade I and II).
Perioperative routines
A consultant anesthetist sees all our patients preoperatively. Elderly patients (>70 
years) and patients on multiple medications are routinely also seen by consultant 
internist, to optimize the general medical condition and medications. Patients with a 
known heart condition are referred to cardiologist for cardiac ultrasound and ECG 
stress test. Patients with a past hematological history are referred to a consultant 
hematologist. Aspirin is stopped at least 10 days prior to surgery and when on 
anticoagulation, the INR should be below 1.5. All patients receive compressive 
stockings the day before surgery and keep them until fully mobilized. At initiation of 
surgery, a second-generation cephalosporin is administered intravenously and 
continued every 90 minutes until the case is completed or the maximum daily dose of 
8 grams is reached. For long cases, erythromycin or a third-generation cephalosporin 
is started after the maximum daily dose of a second-generation cephalosporin is 
reached and continued until completion of the case. Postoperatively, the patients are 
observed in the recovery for 3-6 hours, whereafter they are transferred to a level 2 
bed. After a craniotomy for a supratentorial tumor, the patients are generally 
observed for 24 hours. For infratentorial tumors, the length of observation is minimum 
48 hours. Low-molecularweight heparin is given the first postoperative day. The 
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patients are mobilized either in the afternoon at the day of surgery or on the first 
postoperative day. 
Ethics
The hospitals´ Data Protection Officials approved the study. 
Statistics
Uni- and multivariate logistic regression was used to determine the impact of the 
different independent variables on 30 day mortality, postop hematoma and postop 
infection. The independent variables were binary except for histology where high 
grade glioma was used as the reference category against which all other histology 
classes were compared. The fit of the multivariate models were investigated and 
reported using Pseudo-R2 and the Hosmer-Lemeshow goodness-of-fit test. P-values 
less than 0.05 were considered significant. Stata v10.1 (Stata Corp, Austin, Tx) was 
used for all statistical analyses.
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Results
Patient population
A total of 2630 consecutive craniotomies at the Oslo University Hospital in the time 
period 2003-2008 were included in this study (Table 1). The mean age at surgery 
was 56 years (range 18-89 years), with a male-to-female ratio of 1:1.06. Follow-up 
was 100%. 
Incidence of craniotomies
First-time craniotomies with primary resection were performed in 2073 cases, 483 
cases were reoperations with repeated resection, and 74 cases were open biopsies. 
Thus, the incidence of first-time craniotomy for a brain tumor was 12.8 /100 000 
inhabitants per year and for a repeat resection 3.0 /100 000 inhabitants per year. 
Surgical mortality
The surgical mortality, defined as death within 30 days of surgery, was 2.3% (n=60). 
The cause of death was postoperative hematomas in 21 cases (35.0 %), tumor 
progression in 21 (35.0%), infectious diseases in 8 cases (13.3%), postoperative 
edema and subsequent herniation in 4 cases (6.7%), and other causes in 6 cases 
(10%) (Table 2). The surgical mortality rate for HGG, LGG, meningiomas and 
metastases, was 2.9% (n=24), 1.0% (n=3), 0.9% (n=6) and 4.5% (n=20), 
respectively. 
Using multivariate Cox regression analyses, age>60 (Odds ratio (OR) 1.84, 95%CI 
(1.05, 3.22) , p<0.05) and biopsy compared to resection (OR 4.67, 95%CI (1.80, 
12.14)  p<0.01) were shown to be significantly associated with increased surgical 
mortality (Table 3). Compared to HGG, metastases were associated with a higher 
mortality in the univariate analysis (p<0.01), but this did not reach significance in the 
multivariate analysis. Compared to HGG, meningiomas were associated with a lower 
surgical mortality (p<0.05). 
Postoperative hematomas requiring recraniotomy
The total occurrence of surgically evacuated postoperative hematomas was 2.1% 
(n=54) (Table 4). Of the 54 evacuated hematomas, 23 (42.6%) were intra-cerebral 
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(ICH), 13 (24.1%) were acute epidural (EDH), 2 (3.7%) were acute subdural (aSDH), 
4 (7.4%) were intracerebellar, 1 (1.9%) was in the brain stem, 8 (14.8%) were chronic 
subdural hematomas (cSDH), and 3 (5.6%) were subcutaneous (SC) (Table 4). 
Risk factors for reoperation for postoperative hematomas
Using multivariate Cox regression analyses, age>60 was shown to be significantly 
associated with increased risk of developing postoperative hematoma (OR 2.43 95% 
CI (1.35,4.39), p<0.001) (Table 3). Neither sex, resection vs. biopsy, primary vs. 
secondary craniotomy, nor tumor type were significantly associated with risk of 
developing postoperative hematoma. The occurrence of postoperative hematoma 
was: HGG 2.0% (n=17), LGG 0.7% (n=2), meningiomas 2.3% (n=16), metastases 
2.2% (n=10). 
Time to reoperation for postoperative hematomas
The surgically evacuated hematomas were reoperated within 6 hours in 11 cases 
(20.4%), within 12 hours in 14 cases (25.9%), within 24 hours in 21 cases (38.9%), 
within 48 hours in 35 cases (64.8%), and within 72 hours in 40 cases (74.1%) (Table 
4). Four patients were operated between day 3 and day 7 after surgery, 3 patients 
were operated between day 7 and day 30, and 7 patients after 30 days of surgery. All 
7 in the latter group were cSDH. Excluding the cSDHs, the median time from tumor 
surgery to reoperation for hematoma was 1 day (mean 2.2 days, range 0-26). 
Consequences of postoperative hematoma
Twenty patients (37.0 %) had no additional disability, 16 (29.6 %) had minor 
additional disability, 4 (7.4 %) had major additional disability, and 12 (22.2 %) died 
due to their hematoma. Long-term data are inconclusive for 2 patients (3.7 %). Six 
out of twenty-three (26.1 %) patients with ICH died, while 2/13 (15.4 %) patients with 
EDH died (p>0.05) (Table 4).
Postoperative infection requiring recraniotomy
A total of 39 patients (1.5%) were reoperated for deep postoperative infection (Table 
5). Of these infections, 23 (59.0 %) were extradural (ED), 6 (15.4 %) intradural (ID), 
and 10 (25.6 %) were both intra- and extradural. 
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Risk factors of reoperation for postoperative infection
Multivariate Cox regression analysis demonstrated that meningiomas had an 
increased risk of infection compared to gliomas (odds ratio 5.88, 95%CI (2.47,13.87), 
p<0.001) (Table 3). Men also had an increased risk of infections (p<0.01). Neither 
resection vs. biopsy, nor primary vs. secondary craniotomy were significantly 
associated with risk of developing postoperative deep infection. The postoperative 
infection rate was 1.0% (n=8) for HGG, 0.0% (n=0) for LGG, 3.2% (n=22) for 
meningiomas, and 1.1% (n=5) for metastases. 
Time to reoperation for postoperative infection
The median time from tumor surgery to reoperation for infection was 42 days (mean 
95.7 days, range 16-667 days). The number of patients who were reoperated within 
1, 2, 3, 6 and 12 months, were 11 (28.2%), 27 (69.2%), 29 (74.4%), 32 (82.1%) and 
37 (94.9%), respectively. 
Consequences of postoperative infection
Of the 39 patients with deep infection, 29 (74.4 %) had no additional disability, 5 
(12.8 %) had minor additional disability, 3 (7.7 %) had major additional disability, 2 
(5.1 %) died due to the infection (Table 4).
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Discussion
Epidemiology
The neurosurgical catchment area for Oslo University Hospital (OUH) is well-defined, 
consisting of 2.7 million inhabitants (56% of the Norwegian population) and with very 
little loss of patients (1%) to other health regions or countries (The Norwegian Cancer 
Registry, unpublished data). As all patients ≥18 years who underwent craniotomy for 
an intracranial tumor at OUH within a defined time period of 6 years were included in 
this study, it can serve as a population study in terms of incidence of craniotomies for 
particular tumor types in the Norwegian population. The incidence of first-time 
craniotomy for a brain tumor was 12.8 /100 000 inhabitants per year and for a repeat 
resection 3.0 /100 000 inhabitants per year. 
Surgical mortality at 30 days
The overall surgical mortality in this series was 2.3%. The incidence of surgical 
mortality after craniotomy for tumors is previously reported to be between 0 and 
9.6%, varying with the diagnosis 10, 15, 18-26. Long et al. 23 reported in 2003 a mortality 
rate at high-volume hospitals (>50 craniotomies/year) of 2.5% after craniotomy for 
various intracranial tumors, both benign and malignant. Barker et al. 20 reported in 
their series of primary supratentorial brain tumors a mortality rate of 2.9%. However, 
both these studies were in-hospital mortality rates, whereas we report a 30-day 
mortality rate. Nevertheless, our mortality rates are comparable to, or even lower 
than, most published rates.
The causes of surgical mortality include complications to surgery and factors not 
directly related to surgery, as well as other factors, like tumor progression or other 
morbidity. Several risk factors are associated with increased hazard of death, e.g. 
advanced age 10, 15, 20, 24, a low preoperative KPS score 15, and comorbidity 10, 20. 
Several of the complications are avoidable, and should be paid close attention to. 
Postoperative hematomas carry a high mortality rate 17. In our series, hematomas 
were suspected to be the cause of, or significant contributor to, 35% of the deaths 
within 30 days of surgery. Consequently, avoiding hematomas is the single most 
important factor to reduce surgical mortality.
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Pulmonary embolism (PE) has an incidence rate of between 1.5 and 3%, and a 
mortality rate between 9 and 50%, and is a frequent cause of death among 
neurosurgical patients 27. In our study, one patient died from a PE postoperatively. 
The prevention of PE in neurosurgical patients is controversial, as the commonly 
used medical prophylaxis, i.e. unfractioned or low-molecular-weight heparin, may 
increase the rate of intracranial bleeding, with its deleterious effects 28. Danish et al. 
showed that mechanical prophylaxis yields outcomes in craniotomy patients superior 
of those of heparin 28, but the field remains controversial. In our practice, patients with 
a past hematological history are referred to a consultant hematologist, all patients 
receive compressive stockings the day before surgery and keep them until fully 
mobilized. Low-molecular-weight heparin is given the first postoperative day. The 
patients are mobilized very early, either the same afternoon or on the first 
postoperative day. 
Age is an independent risk factor for surgical mortality. Still, age should not be used 
as a selection criterion for surgery for intracranial tumors alone 29. A careful selection 
among patients with a low preoperative KPS score and with comorbidity should be 
carried out to lower operative mortality rates. 
In our series, undergoing open biopsy was significantly associated with 30-day 
mortality, a finding that probably has more to do with a selection bias that favors 
good candidates for resection, while those undergoing biopsy already have a poorer 
prognosis. A total of 74 patients underwent open biopsy (Table 1). Seven of these 
patients died within 30 days postoperatively (9.5%), the majority of whom (5 of 7, or 
71.4%) died due to tumor progression (Table 2). 
In our series, meningiomas had a significantly lower 30-day mortality rate than HGG 
and metastases, with a rate of 0.9% vs. 2.9% and 4.5%. One factor contributing to 
this difference might be that all 6 deaths in the meningioma group were surgery-
related, while several deaths in the other groups were non-surgery related. However, 
this factor alone does not explain the discrepancy, indicating that the inherent risk of 
undergoing a craniotomy will in fact vary according to the diagnosis. 
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Postoperative hematomas requiring reoperation
In our series, we found a rate of postoperative hematomas of 2.1%. This includes 3 
subcutaneous hematomas and 8 cSDH. Other studies have reported a hematoma 
rate of 0.6-4.0% 15, 18-22, 25, 26, 29, 30. 
Risk factors
Advanced age was significantly associated with development of postoperative 
hematoma, in both uni- and multivariate analyses. This finding is supported by other 
studies 13, 17, 31 and has been attributed to tissue fragility observed in the elderly 28. 
Palmer et al. 17 showed in their series of 6668 intracranial procedures an increased 
risk of postoperative hematoma for meningiomas compared with intrinsic tumors. We 
did not find an association between histology and risk of postoperative hematoma. 
In the aforementioned series, Palmer et al. 17 identified several risk factors associated 
with postoperative hematoma, including thrombocytopenia, anticoagulants, a history 
of heavy alcohol intake, coagulopathy, malignancy outside the central nervous 
system, and the administration of antiplatelet agents during the 2 weeks preceding 
surgery. Administration of antiplatelet agents was the most frequent risk factor, being 
used by 43% of those reoperated for hematoma 17. In our practice, patients with a 
past hematological history are referred to a consultant hematologist, aspirin is 
stopped at least 10 days prior to surgery and when on anticoagulation, the INR 
should be below 1.5. Low-molecular-weight heparin is not given until the first 
postoperative day. 
Mortality rate of postoperative hematomas
The reported mortality rate of postoperative hematomas is 18-32% 17, 32, 33. We found 
a mortality rate of 22%, with an additional 2% being severely disabled due to the 
hematoma. Consequently, postoperative hematomas may have deleterious 
consequences and it is utmost important to reduce or eliminate as many risk factors 
as possible, and thereby reducing the incidence of postoperative hematomas. 
Vassilouthis et al. 34 indicated in their series of 526 patients undergoing craniotomy, 
that the incidence of postoperative intracranial hematoma should become negligible, 
provided that necessary modifications regarding anesthesia are adopted. Their strict 
anesthesiological protocol included a deep opioid analgesia to eliminate any acute 
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elevations of the arterial pressure during and immediately after craniotomy. 
Furthermore, emergence from anaesthesia was delayed for an average of 1 1/2-2 h 
following the neurosurgical procedure. Even though postoperative hematomas occur 
rarely, more studies on how to avoid them are needed, as the consequences of them 
are often devastating. 
Timing of postoperative intracranial hematoma development
Taylor et al. 32 reported a 2.2% rate of postoperative hematomas in their series of 
2305 patients undergoing intracranial surgery of miscellaneous reasons. Clinical 
deterioration as a result of postoperative hematoma occurred within 6 hours of 
surgery in 88% of the cases and <24 hours after surgery in the remaining 12% 
hematoma cases. They concluded that a 6-hour observation period in the recovery 
area/intensive care unit after craniotomy before transfer to further nursing on a 
neurosurgical ward should be sufficient for most patients, but they recommended 
longer observation times after emergency craniotomies and posterior fossa surgery. 
In our series, only 11 patients (25%) were reoperated within 6 hours, indicating that a 
6-hour observation period in recovery may be insufficient to sift out the majority of the 
patients in need of emergency surgery for a postoperative hematoma. However, 
close observation on a specialized neurosurgical ward may overcome this problem. 
Furthermore, our results indicate that a patient undergoing a craniotomy should be 
observed closely for a total of at least 48 hours postoperatively, as 80% of our 
patients that needed a recraniotomy for postoperative hematoma are operated within 
2 days. 
Postoperative infections requiring reoperation
Contemporary neurosurgical series have reported an incidence of postoperative 
infections after craniotomy of 0.6-6.6% 18, 19, 30, 35-37, although some of these series 
have included non-operative cases as well. Our rate of postoperative infections 
requiring surgical treatment was in this study 1.5%, thus being in the lower end of the 
scale. 
Risk factors
We observed a statistically significant association between male gender and 
postoperative infections. This has not been noted in other large neurosurgical series 
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38-40, but Korinek et al. 41 observed an increased risk of nosocomial meningitis after 
craniotomy in males. At present, we have no explanation for our finding. 
Meningioma surgery was significantly associated with development of postoperative 
infection in both uni- and multivariate analyses. This was also shown by Korinek et al. 
35 in 2005, although only in univariate analysis. They attributed this to hemostasis and 
closure difficulties in meningioma surgery. Korinek et al. 35 also showed an 
association between infection and surgery duration over 4 hours, a finding that also 
has been demonstrated by others 42, 43. As meningioma operations are often time 
-consuming procedures, this might be a contributing factor to the higher incidence of 
infections after meningioma surgery. 
Korinek et al. 35 studied the effect of antibiotic prophylaxis (ABP) on neurosurgical site 
infections after craniotomy for various reasons, e.g. tumor surgery, vascular surgery, 
and trauma surgery. Among the 4578 patients studied, 77 (1.7%) developed bone 
flap osteitis, and 126 (2.7%) developed brain abscess or subdural empyema, for a 
total of 4.4%. As patients with both osteitis and abscess/empyema were counted 
once in each group, the number of patients with infections was a bit lower. ABP 
significantly reduced the incidence of bone flap osteitis (3.1% in patients with no ABP 
and 1.3% in patients with ABP, p<0.0002) and abscess/empyema (5.6% versus 
2.0%, p<0.0001). In our practice, we use a second-generation cephalosporin i.v. at 
initiation of surgery and continued every 90 minutes until the case is completed or the 
maximum daily dose of 8 grams is reached, whereafter erythromycin or a third-
generation cephalosporin is started and continued until completion of the case. 
Consequences of postoperative infection
The consequences of postoperative infection are not at all as severe as the 
consequences of postoperative hematoma. In our series, 2 patients (5%) died due to 
the infection, while 33 (85%) had a good outcome, with no or only a mild disability 
(Table 2). It is important to point out that we did not include patients with meningitis. 
Timing of postoperative infection development
In our series, almost 75% of the patients with infection were reoperated within 3 
months of tumor surgery. Korinek et al. 35 showed a mean time between surgery and 
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onset of infection of 118±157 days for bone flap osteitis, and 25±27 days for brain 
abscesses or subdural empyema. Dashti et al. 36 reported a median duration between 
craniotomy and presentation of postoperative infection of 1.5 months (range 4 days-5 
years). In our series, most postoperative infections requiring reoperation occur within 
3 months of surgery, but some infections, in particular bone flap osteitis, may occur 
later than 1 year after surgery, reportedly as late as 5 years later 43, 44. 
Strengths of the study
The strengths of this study lie in the setting, design and follow-up. The data were 
restricted to one health centre only (Oslo University Hospital), thereby reducing the 
possible confounding effect of differences in the access to health care services 
between health centers. Thus, we have avoided the selection bias inherently present 
in large multi-center studies, as there are only two neurosurgical units performing 
these surgeries in a geographically well-defined area. As Dashti et al. 36 pointed out, 
it is reasonable to assume that a number of patients with postoperative infection were 
not included in their study if they presented to, and were subsequently treated at, 
other facilities than the one where they were operated in the first place. They also 
point out that this number might be high, but that there is no way to determine how 
high 36. This problem may have occurred in several of the other studies as well. 
Furthermore, our data were prospectively registered in a database. As the study 
includes all craniotomies performed for a histologically verifiable brain tumor, there is 
no selection bias. The study is contemporary, thereby reflecting current neurosurgical 
practice and was performed within a relatively short time span, thereby reducing 
confounding factors as changes in antibiotic prophylaxis regimen or operating 
theatres. With respect to data, we only used end points that are easily verifiable 
(mortality, reoperation for hematomas, reoperations for infections). Lastly, we 
obtained 100% follow-up. To the best of our knowledge, our study is the largest study 
with regard to postoperative complications within 30 days of craniotomy for brain 
tumors. Previous studies are either smaller than our study, or they use in-hospital 
mortality rates.
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Limitations of the study
The first limitation of the study is the retrospective design. Secondly, the follow-up on 
some patients may be too short with regard to postoperative infections, as bone flap 
infections may occur later than 1 year after surgery. 
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Conclusions
The annual incidence of first-time craniotomy for a brain tumor was 12.8 /100 000 
inhabitants. The mortality rate, rate of postoperative hematomas and infections were 
low. Although advanced age was significantly associated with a higher 30-day 
surgical mortality and risk of postoperative hematomas, surgery in selected elderly 
patients is worthwhile and not futile. The single most important way to reduce 
surgical mortality is avoidance of postoperative hematomas. 
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Table 1: Patient characteristics
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N %
Patients
Department
   Rikshospitalet
   Ullevål
Sex
   Male
   Female
Age (years)
   18 –29.9
   30 - 39.9
   40 –49.9
   50 – 59.9
   60 – 69.9
   70 – 79.9
      >80
Type of surgery
   Primary
   Second
Craniotomy
   Resection
   Open biopsy
Main histology
   High-grade glioma (HGG)
   Meningioma
   Metastases
   Low-grade glioma (LGG)
   Schwannoma  
   Primary CNS-lymphoma
   CNS hemangioblastoma
   Cavernous hemangioma
   Pituitary adenoma  
   Others
2630
1693
937
1275
1355
141
300
437
604
649
411
88
2141
489
2556
74
830
693
449
289
73
51
39
38
8
160
100
64.4
35.6
48.5
51.5
5.4
11.4
16.6
23.0
24.7
15.6
3.3
81.4
18.6
97.2
2.8
31.6
26.3
17.1
11.0
2.8
1.9
1.5
1.4
0.3
6.1
Table 2: Patients who died within 30 days of tumor surgery (surgical mortality cases) 
(n=60)
Age Sex Histology* Op.type** Time*** Comments
43 M Hemangioblastoma R 3 Postop. hematoma
29 F HGG R 17 Tumor progression
41 M HGG R 13 Postop. brain edema/herniation
41 F HGG R 3 Postop. hematoma
48 M HGG B 10 Pneumonia
49 F HGG R 11 Tumor progression
54 F HGG R 2 Tumor progression
56 F HGG B 8 Postop. hematoma
60 M HGG R 30 Postop. hematoma
64 M HGG R 17 Tumor progression
64 F HGG R 4 Postop. brain edema/herniation
65 F HGG R 22 Postop. hematoma
66 F HGG R 24 Tumor progression
67 F HGG R 5 Tumor progression
67 M HGG R 19 Tumor progression
69 M HGG B 29 Tumor progression
74 F HGG R 30 Tumor progression
75 M HGG R 11 Postop. hematoma
75 M HGG R 22 Tumor progression
76 M HGG R 15 Postop. hematoma
76 F HGG R 4 Postop. hematoma
77 F HGG R 8 Postop. hematoma
81 F HGG B 28 Tumor progression
82 M HGG R 21 Pulmonary embolism
84 F HGG R 14 Postop. brain edema/herniation
32 F LGG R 17 Shunt failure
48 M LGG R 18 Pneumonia
68 M LGG R 24 Postop. hematoma
62 M Lymphoma B 12 Tumor progression
75 F Lymphoma B 13 Tumor progression
78 M Lymphoma B 26 Tumor progression
31 F Melanocytoma R 11 Tumor progression
55 F Meningioma R 6 Postop. brain edema/herniation
73 M Meningioma R 11 Postop. hematoma
77 M Meningioma R 4 Postop. hematoma
79 F Meningioma R 12 Postop. hematoma
83 M Meningioma R 15 Pneumonia
83 M Meningioma R 29 Cardiac arrest
35 M Metastasis R 12 Tumor progression
40 M Metastasis R 27 Pneumonia
45 F Metastasis R 4 Postop. hematoma
46 F Metastasis R 9 Hydrocephalus
49 F Metastasis R 25 Postop. hematoma
49 F Metastasis R 26 Postop. hematoma
52 M Metastasis R 6 Postop. hematoma
53 F Metastasis R 5 Tumor progression
56 M Metastasis R 3 Cardiac arrest
60 M Metastasis R 1 Postop. hematoma
61 M Metastasis R 30 Postop. hematoma
61 F Metastasis R 12 Pneumonia
27
62 M Metastasis R 19 Tumor progression
62 M Metastasis R 29 Postop. hematoma
65 F Metastasis R 22 Sepsis
71 F Metastasis R 25 Tumor progression
73 M Metastasis R 24 Sepsis
77 F Metastasis R 19 Tumor progression
78 M Metastasis R 29 Subdural empyema
81 F Metastasis R 25 Tumor progression
48 M Pituitary adenoma R 16 Cerebral infarction
69 M Pituitary adenoma R 9 Postop. hematoma
Abbreviations:
M = male, F = female
*Histology: HGG = high-grade glioma, LGG = low-grade glioma
**Op. type = Resection (R) or biopsy (B)
***Time = Time to death in days after primary surgery
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Table 3. Univariate and multivariate analysis of factors possibly associated with 
surgical mortality, surgery for postoperative infection and surgery for postoperative 
hematoma
30 day mortality Infection Postop hematoma
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Odds Ratio (95% 
CI)
Odds Ratio 
(95% CI)
Odds Ratio (95% 
CI)
Odds Ratio (95% 
CI)
Odds Ratio (95% 
CI)
Odds Ratio (95% 
CI)
Age >60 2.27** 1.84* 1.11 0.97 2.42** 2.43**
No/Yes [1.34,3.86] [1.05,3.22] [0.59,2.09] [0.50,1.86] [1.38,4.26] [1.35,4.39]
Sex 0.94 1.09 0.47* 0.33** 0.94 0.94
Male/Female [0.56,1.57] [0.64,1.84] [0.24,0.91] [0.16,0.66] [0.55,1.61] [0.54,1.64]
Primary Op 0.77 1.01 1.74 2.01 0.99 1.14
Primary/secondary [0.38,1.57] [0.48,2.13] [0.86,3.51] [0.97,4.17] [0.50,1.99] [0.56,2.31]
Operation 4.93*** 4.67** a) a) a) a)
Resection/Biopsy [2.16,11.26] [1.80,12.14]
Histology
HGG 1 1 1 1 1 1
LGG 0.53 0.44 a) a) 0.38 0.59
[0.16,1.69] [0.13,1.53] [0.09,1.58] [0.13,2.66]
Meningioma 0.30** 0.30* 3.70*** 4.61*** 1.18 1.08
[0.13,0.71] [0.12,0.76] [1.95,7.02] [1.98,10.73] [0.65,2.13] [0.53,2.19]
Metastasis 2.50** 1.51 0.71 1.34 1.11 0.95
[1.44,4.31] [0.81,2.80] [0.28,1.83] [0.43,4.21] [0.55,2.22] [0.43,2.10]
Lymphoma 2.77 0.91 1.34 3.43 a) a)
[0.84,9.14] [0.23,3.64] [0.18,9.94] [0.41,28.80]
Capillary 
hemangioblastoma
1.13 1.01 a) a) 2.64 2.67
[0.15,8.37] [0.13,7.72] [0.62,11.24] [0.59,12.12]
Schwannoma 0.42 0.40 0.43 0.75 1.00 1.21
[0.13,1.34] [0.12,1.34] [0.10,1.79] [0.16,3.56] [0.42,2.36] [0.47,3.15]
Others 0.42 0.40 0.92 1.61 0.66 0.76
[0.13,1.34] [0.12,1.36] [0.12,6.80] [0.20,13.19] [0.09,4.81] [0.10,5.84]
Observations 2557 2286 2523
Pseudo-R2 0,064 0,069 0,025
H-L test p =0.66 p=0.85 P=0.78
HGG=High grade glioma
LGG=Low grade glioma
H-L= Hosmer-Lemeshow
a) Insufficient events in one of the contrasting categories to calculate odds ratio
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Table 4. Patients reoperated for postoperative hematoma (n=54)
Age Sex Histology* Location** Time to reop (hh:mm)*** Outcome**** Time to death 
(days)*****
63 F Carcinoma SC 19:45 NAD
65 M Carcinoma EDH 69:53 Minor
43 M Hemangioblastoma Brain stem 28:35 Death 3
77 M Hemangioblastoma Cerebellum 47:04 NAD
31 M HGG ICH 14:15 NAD
33 M HGG cSDH 107 days NAD
34 M HGG Cerebellum 152:57 Minor
46 F HGG EDH 26:22 NAD
48 F HGG ICH 01:36 Minor
55 F HGG ICH 06:20 Minor
57 M HGG cSDH 43 days NAD
58 M HGG ICH 44:10 NA
65 F HGG ICH 16:58 Death 22
70 F HGG EDH 74:25 NAD
72 F HGG EDH 02:50 Minor
75 M HGG ICH 01:35 Death 11
76 M HGG SC 03:15 NAD
76 F HGG ICH 30:38 Minor
76 F HGG ICH 04:12 Death 4
77 F HGG EDH 07:57 Death 8
81 M HGG EDH 30:17 Minor
51 M LGG EDH 46:06 Minor
60 F LGG ICH 27:35 NAD
52 M Melanocytoma EDH 42:45 NAD
51 M Meningioma EDH 48:50 NAD
52 F Meningioma aSDH 10 days NAD
54 F Meningioma ICH 93:35 Major
60 F Meningioma ICH 02:20 Minor
67 F Meningioma ICH 14:20 Minor
69 F Meningioma ICH 01:45 NAD
69 F Meningioma cSDH 47 days NAD
69 F Meningioma ICH 22:00 Minor
70 M Meningioma SC 06:20 NAD
70 M Meningioma cSDH 73 days NAD
71 F Meningioma Cerebellum 22:20 Major
75 F Meningioma ICH 167:45 NA
76 M Meningioma ICH 03:27 Major
78 M Meningioma ICH 03:40 Minor
78 F Meningioma cSDH 383 days Death 390
80 F Meningioma cSDH 13 days Minor
45 F Metastasis ICH 45:20 Death 4
49 F Metastasis ICH 26 days Death 26
52 M Metastasis EDH 17:41 Death 6
54 M Metastasis EDH 53:07 NAD
61 M Metastasis Cerebellum 38:05 Death 30
63 F Metastasis ICH 32:40 Minor
68 M Metastasis ICH 03:40 Minor
72 F Metastasis EDH 04:15 NAD
73 F Metastasis cSDH 68 days NAD
30
73 M Metastasis ICH 47:17 Death 54
62 M Pituitary adenoma ICH 58:10 Major
69 M Pituitary adenoma aSDH 45:15 Death 9
69 M Pituitary adenoma cSDH 107 days Minor
46 M Schwannoma EDH 61:08 NAD
Abbreviations:
M = male, F = female
*Histology: HGG = high-grade glioma, LGG = low-grade glioma
**Location of hematoma: SC = subcutaneous hematoma, EDH = epidural hematoma, aSDH = acute 
subdural hematoma, cSDH = chronic subdural hematoma, ICH = intracerebral hematoma
***Time = time of reoperation in hours and minutes after primary surgery
****Outcome = hematoma-inflicted disability: NAD = no additional disability, Minor = minor additional 
disability, Major = major additional disability, NA = no information available
*****Time to death = time from tumor surgery to death, when caused by the hematoma
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Table 5. Patients reoperated for postoperative infections (n=39)
Age Sex Histology* Location** Time to reop. (days)*** Outcome****
18 M HGG ED 16 NAD
40 M HGG ED 46 NAD
57 M HGG ED 20 NAD
59 M HGG ED 307 NAD
64 M HGG ED 49 Death
69 M HGG ED 80 Major
70 M HGG ED 20 NAD
70 F HGG ID 25 NAD
34 M Lymfoma ED 667 NAD
26 F Meningioma ED 71 NAD
33 F Meningioma ED 119 NAD
38 M Meningioma ED 248 NAD
40 F Meningioma ED 270 NAD
42 F Meningioma ED/ID 25 Minor
49 M Meningioma ED/ID 29 NAD
51 M Meningioma ID 31 NAD
53 F Meningioma ED 42 NAD
55 M Meningioma ED 18 NAD
56 M Meningioma ID 45 NAD
56 F Meningioma ED/ID 38 Minor
56 M Meningioma ED 35 NAD
58 M Meningioma ED 59 NAD
64 M Meningioma ID 59 NAD
66 M Meningioma ED/ID 40 NAD
71 M Meningioma ED/ID 37 NAD
72 M Meningioma ED 37 NAD
74 F Meningioma ED 190 Minor
74 M Meningioma ID 36 NA
75 M Meningioma ED/ID 38 NAD
76 M Meningioma ED/ID 56 NAD
78 F Meningioma ED 17 Minor
45 M Metastasis ED/ID 25 NAD
59 F Metastasis ED/ID 116 Minor
63 M Metastasis ED 25 NAD
71 M Metastasis ED/ID 109 Major
78 M Metastasis ID 20 Death
66 F Other (MFH) ED 393 NAD
62 M Pituitary adenoma ED 232 Major
40 F Schwannoma ED 43 NAD
Abbreviations:
M = male, F = female
*Histology: HGG = high-grade glioma, LGG = low-grade glioma
**Location = location of infection: ED = extradural infection, ID = intradural infection, ED/ID = both 
intradural and extradural infection
***Time = time of reoperation in days after primary surgery
****Outcome = clinical outcome after postoperative infection: NAD = no additional disability, Minor = 
minor additional disability, Major = major additional disability. 
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